2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Leukemia, Myeloid, Acute
124
Multiple Myeloma
84
Precursor Cell Lymphoblastic Leukemia-Lymphoma
76
Lymphoma
73
Lymphoma, Non-Hodgkin
66
Leukemia
66
Myelodysplastic Syndromes
56
Hodgkin Disease
53
Lymphoma, Large B-Cell, Diffuse
37
Lymphoma, Mantle-Cell
33
Breast Neoplasms
32
Neuroblastoma
30
Leukemia, Lymphocytic, Chronic, B-Cell
30
Burkitt Lymphoma
30
Lymphoma, Follicular
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26
Recurrence
24
Sarcoma
18
Neoplasms, Plasma Cell
18
Hematologic Neoplasms
18
Central Nervous System Neoplasms
18
Lymphoma, B-Cell, Marginal Zone
17
Leukemia, Biphenotypic, Acute
16
Myeloproliferative Disorders
15
Lymphoma, Large-Cell, Immunoblastic
15
Congenital Abnormalities
15
Brain Neoplasms
14
Leukemia, Myelomonocytic, Chronic
13
Anemia, Refractory, with Excess of Blasts
13
Medulloblastoma
12
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts